2369 related articles for article (PubMed ID: 27445146)
1. Activation of β-Glucocerebrosidase Reduces Pathological α-Synuclein and Restores Lysosomal Function in Parkinson's Patient Midbrain Neurons.
Mazzulli JR; Zunke F; Tsunemi T; Toker NJ; Jeon S; Burbulla LF; Patnaik S; Sidransky E; Marugan JJ; Sue CM; Krainc D
J Neurosci; 2016 Jul; 36(29):7693-706. PubMed ID: 27445146
[TBL] [Abstract][Full Text] [Related]
2. Glucocerebrosidase gene therapy prevents α-synucleinopathy of midbrain dopamine neurons.
Rocha EM; Smith GA; Park E; Cao H; Brown E; Hayes MA; Beagan J; McLean JR; Izen SC; Perez-Torres E; Hallett PJ; Isacson O
Neurobiol Dis; 2015 Oct; 82():495-503. PubMed ID: 26392287
[TBL] [Abstract][Full Text] [Related]
3. Increased Lysosomal Exocytosis Induced by Lysosomal Ca
Tsunemi T; Perez-Rosello T; Ishiguro Y; Yoroisaka A; Jeon S; Hamada K; Rammonhan M; Wong YC; Xie Z; Akamatsu W; Mazzulli JR; Surmeier DJ; Hattori N; Krainc D
J Neurosci; 2019 Jul; 39(29):5760-5772. PubMed ID: 31097622
[TBL] [Abstract][Full Text] [Related]
4. A novel glucosylceramide synthase inhibitor attenuates alpha synuclein pathology and lysosomal dysfunction in preclinical models of synucleinopathy.
Cosden M; Jinn S; Yao L; Gretzula CA; Kandebo M; Toolan D; Hatcher NG; Ma L; Lemaire W; Adam GC; Burlein C; Minnick C; Flick R; Watt ML; Mulhearn J; Fraley M; Drolet RE; Marcus JN; Smith SM
Neurobiol Dis; 2021 Nov; 159():105507. PubMed ID: 34509608
[TBL] [Abstract][Full Text] [Related]
5. A modulator of wild-type glucocerebrosidase improves pathogenic phenotypes in dopaminergic neuronal models of Parkinson's disease.
Burbulla LF; Jeon S; Zheng J; Song P; Silverman RB; Krainc D
Sci Transl Med; 2019 Oct; 11(514):. PubMed ID: 31619543
[TBL] [Abstract][Full Text] [Related]
6. Parkinson's disease: acid-glucocerebrosidase activity and alpha-synuclein clearance.
Blanz J; Saftig P
J Neurochem; 2016 Oct; 139 Suppl 1():198-215. PubMed ID: 26860955
[TBL] [Abstract][Full Text] [Related]
7. A New Glucocerebrosidase Chaperone Reduces α-Synuclein and Glycolipid Levels in iPSC-Derived Dopaminergic Neurons from Patients with Gaucher Disease and Parkinsonism.
Aflaki E; Borger DK; Moaven N; Stubblefield BK; Rogers SA; Patnaik S; Schoenen FJ; Westbroek W; Zheng W; Sullivan P; Fujiwara H; Sidhu R; Khaliq ZM; Lopez GJ; Goldstein DS; Ory DS; Marugan J; Sidransky E
J Neurosci; 2016 Jul; 36(28):7441-52. PubMed ID: 27413154
[TBL] [Abstract][Full Text] [Related]
8. Acid ceramidase involved in pathogenic cascade leading to accumulation of α-synuclein in iPSC model of GBA1-associated Parkinson's disease.
Kumar M; Srikanth MP; Deleidi M; Hallett PJ; Isacson O; Feldman RA
Hum Mol Genet; 2023 May; 32(11):1888-1900. PubMed ID: 36752535
[TBL] [Abstract][Full Text] [Related]
9. Acid ceramidase inhibition ameliorates α-synuclein accumulation upon loss of GBA1 function.
Kim MJ; Jeon S; Burbulla LF; Krainc D
Hum Mol Genet; 2018 Jun; 27(11):1972-1988. PubMed ID: 29579237
[TBL] [Abstract][Full Text] [Related]
10. Molecular mechanisms of α-synuclein and GBA1 in Parkinson's disease.
Stojkovska I; Krainc D; Mazzulli JR
Cell Tissue Res; 2018 Jul; 373(1):51-60. PubMed ID: 29064079
[TBL] [Abstract][Full Text] [Related]
11. Glucocerebrosidase Activity Modulates Neuronal Susceptibility to Pathological α-Synuclein Insult.
Henderson MX; Sedor S; McGeary I; Cornblath EJ; Peng C; Riddle DM; Li HL; Zhang B; Brown HJ; Olufemi MF; Bassett DS; Trojanowski JQ; Lee VMY
Neuron; 2020 Mar; 105(5):822-836.e7. PubMed ID: 31899072
[TBL] [Abstract][Full Text] [Related]
12. A double-hit in vivo model of GBA viral microRNA-mediated downregulation and human alpha-synuclein overexpression demonstrates nigrostriatal degeneration.
Polissidis A; Koronaiou E; Nikolopoulou G; Viel C; Nikatou M; Bogiongko M; Sardi SP; Xilouri M; Vekrellis K; Stefanis L
Neurobiol Dis; 2022 Feb; 163():105612. PubMed ID: 34995756
[TBL] [Abstract][Full Text] [Related]
13. Loss of glucocerebrosidase 1 activity causes lysosomal dysfunction and α-synuclein aggregation.
Bae EJ; Yang NY; Lee C; Lee HJ; Kim S; Sardi SP; Lee SJ
Exp Mol Med; 2015 Mar; 47(3):e153. PubMed ID: 25813221
[TBL] [Abstract][Full Text] [Related]
14. α-Synuclein-induced lysosomal dysfunction occurs through disruptions in protein trafficking in human midbrain synucleinopathy models.
Mazzulli JR; Zunke F; Isacson O; Studer L; Krainc D
Proc Natl Acad Sci U S A; 2016 Feb; 113(7):1931-6. PubMed ID: 26839413
[TBL] [Abstract][Full Text] [Related]
15. Lysosomal trafficking defects link Parkinson's disease with Gaucher's disease.
Wong YC; Krainc D
Mov Disord; 2016 Nov; 31(11):1610-1618. PubMed ID: 27619775
[TBL] [Abstract][Full Text] [Related]
16. LRRK2 kinase activity regulates lysosomal glucocerebrosidase in neurons derived from Parkinson's disease patients.
Ysselstein D; Nguyen M; Young TJ; Severino A; Schwake M; Merchant K; Krainc D
Nat Commun; 2019 Dec; 10(1):5570. PubMed ID: 31804465
[TBL] [Abstract][Full Text] [Related]
17. Lysosomal functions and dysfunctions: Molecular and cellular mechanisms underlying Gaucher disease and its association with Parkinson disease.
Horowitz M; Braunstein H; Zimran A; Revel-Vilk S; Goker-Alpan O
Adv Drug Deliv Rev; 2022 Aug; 187():114402. PubMed ID: 35764179
[TBL] [Abstract][Full Text] [Related]
18. Glucocerebrosidase deficiency promotes release of α-synuclein fibrils from cultured neurons.
Gegg ME; Verona G; Schapira AHV
Hum Mol Genet; 2020 Jun; 29(10):1716-1728. PubMed ID: 32391886
[TBL] [Abstract][Full Text] [Related]
19. Selective loss of glucocerebrosidase activity in sporadic Parkinson's disease and dementia with Lewy bodies.
Chiasserini D; Paciotti S; Eusebi P; Persichetti E; Tasegian A; Kurzawa-Akanbi M; Chinnery PF; Morris CM; Calabresi P; Parnetti L; Beccari T
Mol Neurodegener; 2015 Mar; 10():15. PubMed ID: 25881142
[TBL] [Abstract][Full Text] [Related]
20. Glucocerebrosidase dysfunction in neurodegenerative disease.
Brooker SM; Krainc D
Essays Biochem; 2021 Dec; 65(7):873-883. PubMed ID: 34528667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
